Patents by Inventor William J. Geese
William J. Geese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240190963Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: September 15, 2023Publication date: June 13, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, Yali Fu, William J. Geese, George A. Green, IV, Diane Healey, Sabine Maier, Faith E. Nathan, Abderrahim Oukessou, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Patent number: 11919957Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: GrantFiled: October 17, 2022Date of Patent: March 5, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, William J. Geese, Sabine Maier, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Publication number: 20230295302Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: October 17, 2022Publication date: September 21, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, William J. GEESE, Sabine MAIER, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
-
Publication number: 20230295737Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: December 7, 2022Publication date: September 21, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, Yali FU, William J. GEESE, George A. GREEN, Diane HEALEY, Sabine MAIER, Faith E. NATHAN, Abderrahim OUKESSOU, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
-
Publication number: 20230279114Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: ApplicationFiled: January 30, 2023Publication date: September 7, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
-
Patent number: 11566073Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: GrantFiled: June 1, 2018Date of Patent: January 31, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Robin Edwards, William J. Geese, Danielle M. Greenawalt
-
Publication number: 20210101980Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: March 30, 2018Publication date: April 8, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, Yali FU, William J. GEESE, George A. GREEN, IV, Diane HEALEY, Sabine MAIER, Faith E. NATHAN, Abderrahim OUKESSOU, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
-
Publication number: 20210032344Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: March 29, 2019Publication date: February 4, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, Yali Fu, William J. Geese, George A. Green, IV, Diane Healey, Sabine Maier, Faith E. Nathan, Abderrahim Oukessou, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Publication number: 20200239577Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the SCLC Study TMB subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: October 15, 2018Publication date: July 30, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, William J. GEESE, Sabine MAIER, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
-
Publication number: 20200109204Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: ApplicationFiled: June 1, 2018Publication date: April 9, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
-
Patent number: 7598029Abstract: The invention provides a novel in vitro method for identifying HIV-1 protease inhibitors with reduced potential for inducing metabolic abnormalities. The invention further provides diagnostic methods for identifying patients who may be at risk of developing metabolic abnormalities subsequent to the administration of an HIV-1 protease inhibitor. The invention also provides novel polynucleotides associated with the incidence of HIV-1 protease inhibitor induced metabolic abnormalities. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.Type: GrantFiled: December 22, 2008Date of Patent: October 6, 2009Assignee: Bristol-Myers Squibb CompanyInventors: William J. Geese, Koustubh Ranade
-
Publication number: 20090117535Abstract: The invention provides a novel in vitro method for identifying HIV-1 protease inhibitors with reduced potential for inducing metabolic abnormalities. The invention further provides diagnostic methods for identifying patients who may be at risk of developing metabolic abnormalities subsequent to the administration of an HIV-1 protease inhibitor. The invention also provides novel polynucleotides associated with the incidence of HIV-1 protease inhibitor induced metabolic abnormalities. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.Type: ApplicationFiled: December 22, 2008Publication date: May 7, 2009Inventors: William J. Geese, Koustubh Ranade
-
Patent number: 7482124Abstract: The invention provides novel polynucleotides and polypeptides associated with the incidence of PPAR-agonist induced edema. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polynucleotides and polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly PPAR-agonist induced edema or related indications.Type: GrantFiled: July 7, 2006Date of Patent: January 27, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Koustubh Ranade, Terrye Aigeldinger Delmonte, William J. Geese